Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cengild Medical BhdXKLS:0243 62 3-Year EBITDA Growth Rate is 3.60% as of Mar. 2026, which is 84% below its 10-year median of 22.90. GuruFocus rates XKLS:0243 with a GF Score™ of 62/100 and a GF Value™ of RM0.29 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Cengild Medical Bhd ranks worse than 63.69% on this metric.
During the past 12 months, Cengild Medical Bhd's average EBITDA Per Share Growth Rate was -23.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 12.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cengild Medical Bhd was 128.90% per year. The lowest was 2.70% per year. And the median was 22.90% per year.
Cengild Medical Bhd (XKLS:0243) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cengild Medical Bhd 3-Year EBITDA Growth Rate Related Terms
XKLS:0243 vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Cengild Medical Bhd's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cengild Medical Bhd 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cengild Medical Bhd's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cengild Medical Bhd's 3-Year EBITDA Growth Rate falls into.
Cengild Medical Bhd 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.60% mean?
Cengild Medical Bhd (XKLS:0243) has a 3-Year EBITDA Growth Rate of 3.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cengild Medical Bhd and its competitors. This is 84% below median its historical median of 22.90. Over the past decade, Cengild Medical Bhd's 3-Year EBITDA Growth Rate has ranged from 2.70 to 128.90. According to the industry distribution chart, Cengild Medical Bhd ranks #335 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 63.7%.
Is Cengild Medical Bhd's 3-Year EBITDA Growth Rate too high?
Cengild Medical Bhd's current 3-Year EBITDA Growth Rate of 3.60% is 84% below median its 10-year median of 22.90. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 128.90. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. Cengild Medical Bhd's value of 3.60% is 64.2% below this industry median. Based on the distribution chart, Cengild Medical Bhd ranks #335 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Cengild Medical Bhd has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cengild Medical Bhd's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cengild Medical Bhd ranks #335 out of 526 companies for 3-Year EBITDA Growth Rate. This places Cengild Medical Bhd in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. Cengild Medical Bhd's value of 3.60% is 64.2% below this benchmark. Historically, Cengild Medical Bhd's own 3-Year EBITDA Growth Rate has ranged from 2.70 to 128.90 over the past decade. While the company's 10-year median is 22.90 vs. the industry median of 10.05, Cengild Medical Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cengild Medical Bhd's current 3-Year EBITDA Growth Rate of 3.60% is 64.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cengild Medical Bhd and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cengild Medical Bhd's current 3-Year EBITDA Growth Rate is 3.60%, which is 84% below median its own 10-year median of 22.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cengild Medical Bhd stock overvalued right now?
Based on GuruFocus' analysis, Cengild Medical Bhd (XKLS:0243) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.29, compared to a current price of RM0.20 — trading 32.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.60%, which is 84% below median its 10-year median of 22.90 and 64.2% below the Healthcare Providers & Services industry median of 10.05. Cengild Medical Bhd's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cengild Medical Bhd (XKLS:0243), the current 3-Year EBITDA Growth Rate is 3.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cengild Medical Bhd (XKLS:0243) Overvalued in 2026?
Based on GuruFocus' analysis, Cengild Medical Bhd stock appears to be undervalued.
The current stock price of RM0.20 is trading 32.8% below its estimated GF Value™ of RM0.29.
GuruFocus considers Cengild Medical Bhd to be Significantly Undervalued.
Key valuation signals for XKLS:0243:
3-Year EBITDA Growth Rate: 3.60% (84% below median its 10-year median of 22.90)
GF Value™: RM0.29 vs. price of RM0.20 (32.8% below fair value)
Industry Position: 64.2% below the Healthcare Providers & Services median (#335 of 526)
No single metric tells the full story. See the XKLS:0243 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cengild Medical Bhd is a healthcare service provider operating a medical centre specializing in the diagnosis and treatment of gastrointestinal-related diseases, oncology, gynecology services., liver diseases, and obesity. The company operates in Malaysia and has two reportable segments, Consultant Services and Medical Management Services. A substantial portion of the overall revenue is generated from its Medical Management Services segment.
62GF Score
Get the complete analysis for XKLS:0243
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0243 has been successfully added to your 
